Fulgent Genetics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2017 Annual Meeting of Stockholders held by Fulgent Genetics, Inc. on May 16, 2017. The record date for the meeting was March 24, 2017, with 17,676,256 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A quorum of 79% (13,888,119 shares) was present. Stockholders voted on three proposals:
- Proposal 1 (Election of Directors): Four directors were elected to one-year terms. Ming Hsieh received the highest support with 12,164,297 votes "For," while Yun Yen received 11,363,521 votes "For."
- Proposal 2 (Ratification of Auditors): Stockholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, with 13,852,976 votes "For" and only 4,851 votes "Against."
- Proposal 3 (Reduction of Authorized Shares): Stockholders approved an amendment to the certificate of incorporation to reduce the number of authorized common shares from 200,000,000 to 50,000,000. The proposal passed with 12,546,348 votes "For" and 426 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the reduction of authorized shares from 200 million to 50 million has been legally finalized.
- Verification of the specific terms of the one-year director terms elected.
- Review of the company's subsequent filings for financial performance data, as this 8-K contains no financial metrics.